BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$8.19

52W Range

$4.03 - $8.88

50D Avg

$7.75

200D Avg

$6.49

Market Cap

$1.62B

Avg Vol (3M)

$1.94M

Beta

1.89

Div Yield

-

BCRX Company Profile


BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

536

IPO Date

Mar 04, 1994

Website

BCRX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$324.70M$267.71M-
Collaborative And Other Research And Development$6.72M$214.00K-
Milestone---
Collaborative and Other Research and Development--$5.92M

Fiscal year ends in Dec 23 | Currency in USD

BCRX Financial Summary


Dec 23Dec 22Dec 21
Revenue$331.41M$270.83M$157.17M
Operating Income$-103.71M$-148.44M$-177.72M
Net Income$-226.54M$-247.12M$-184.06M
EBITDA$-103.71M$-143.31M$-177.66M
Basic EPS$-1.18$-1.38$-1.03
Diluted EPS$-1.18$-1.38$-1.03

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 04, 24 | 11:00 AM
Q2 24Aug 05, 24 | 11:44 AM
Q1 24May 06, 24 | 11:42 AM

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
TGTXTG Therapeutics, Inc.
AVXLAnavex Life Sciences Corp.
ATRAAtara Biotherapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
MCRBSeres Therapeutics, Inc.
VKTXViking Therapeutics, Inc.
AXSMAxsome Therapeutics, Inc.
BIVIBioVie Inc.
SAVACassava Sciences, Inc.
CGTXCognition Therapeutics, Inc.
PIRSPieris Pharmaceuticals, Inc.
IMUXImmunic, Inc.
KZRKezar Life Sciences, Inc.
KRTXKaruna Therapeutics, Inc.
INMBINmune Bio, Inc.
MDGLMadrigal Pharmaceuticals, Inc.